^
    3ms
    Individualizing Corticosteroid Use in Pneumonia (clinicaltrials.gov)
    P2, N=24, Completed, Mayo Clinic | Recruiting --> Completed | Trial completion date: Dec 2026 --> Apr 2026 | Trial primary completion date: Dec 2026 --> Apr 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    dexamethasone
    3ms
    CAC-PPCL-001: A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, Institute of Hematology & Blood Diseases Hospital, China | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • bortezomib • dexamethasone
    3ms
    Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone (clinicaltrials.gov)
    P3, N=11, Terminated, Alliance for Clinical Trials in Oncology
    Trial completion date • Trial termination
    |
    lenalidomide • Ninlaro (ixazomib) • dexamethasone • zoledronic acid
    3ms
    19-C-0042: Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jun 2029
    Trial completion date
    |
    Rituxan (rituximab) • dexamethasone • Ruxience (rituximab-pvvr) • Lumoxiti (moxetumomab pasudotox) • aspirin
    3ms
    SIPDEX: Local Dexamethasone Administration in Symptomatic Irreversible Pulpitis (clinicaltrials.gov)
    P=N/A, N=84, Recruiting, Marmara University
    New trial
    |
    dexamethasone
    3ms
    MARINA: A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (R/RMM) (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, iOMEDICO AG | Not yet recruiting --> Recruiting
    Enrollment open
    |
    dexamethasone • Melflufen (melphalan flufenamide)
    3ms
    SURTHODEX: DEXAMETHASONE for Non-urgent Thoracic Surgery (clinicaltrials.gov)
    P=N/A, N=0, Withdrawn, Centre Hospitalier Universitaire, Amiens | N=1600 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    dexamethasone
    3ms
    Effect of acupoint injection on olfactory dysfunction and apoptosis of olfactory mucosal cells in rats with allergic rhinitis (PubMed, Zhen Ci Yan Jiu)
    Acupoint injection can significantly improve olfactory function and olfactory mucosal damage in rats with AR olfactory dysfunction, which may be related to its functions in inhibiting the inflammatory damage and reducing cell apoptosis of the olfactory mucosa.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • IL17A (Interleukin 17A) • IL13 (Interleukin 13) • IL4 (Interleukin 4) • IL5 (Interleukin 5)
    |
    dexamethasone
    3ms
    GEM21menos65: NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide (clinicaltrials.gov)
    P3, N=480, Recruiting, PETHEMA Foundation | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • bortezomib • dexamethasone • Sarclisa (isatuximab-irfc) • iberdomide (CC-220)
    3ms
    GASPING: Giving Asthmatics Intramuscular Steroids for Preventing Return to the Emergency Department (clinicaltrials.gov)
    P4, N=182, Not yet recruiting, Montefiore Medical Center | Trial completion date: Sep 2026 --> Dec 2026 | Initiation date: Apr 2026 --> Jul 2026 | Trial primary completion date: Sep 2026 --> Dec 2026
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    prednisone • dexamethasone
    3ms
    Liposomal Bupivacaine Plus Plain Bupivacaine Versus Dexamethasone Plus Plain Bupivacaine in the Supraclavicular Brachial Plexus Block in Patients With Risk Factors for Severe Acute Postoperative Pain (clinicaltrials.gov)
    P3, N=90, Not yet recruiting, The University of Hong Kong
    New P3 trial
    |
    dexamethasone
    3ms
    Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) (clinicaltrials.gov)
    P1/2, N=1200, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • carboplatin • docetaxel • Lenvima (lenvatinib) • enzalutamide • abiraterone acetate • etoposide IV • prednisone • dexamethasone • Welireg (belzutifan) • vibostolimab/pembrolizumab (MK-7684A)